Fibrinogen supplementation after cardiac surgery: insights from the Zero-Plasma trial (ZEPLAST) M Ranucci, E Baryshnikova British Journal of Anaesthesia Volume 116, Issue 5, Pages 618-623 (May 2016) DOI: 10.1093/bja/aev539 Copyright © 2016 The Author(s) Terms and Conditions
Fig 1 Linear regression analyses for association between FIBTEM maximum clot firmness (MCF) and Clauss fibrinogen concentration. (a) Overall population. (b) Separate analysis for supplemented and unsupplemented subjects. Blue dots: unsupplemented subjects; green triangles: supplemented subjects. British Journal of Anaesthesia 2016 116, 618-623DOI: (10.1093/bja/aev539) Copyright © 2016 The Author(s) Terms and Conditions
Fig 2 Receiver operating characteristics analysis for (a) FIBTEM MCF and (b) Clauss fibrinogen concentration. Outcome variable: severe bleeding. FIBTEM MCF values after placebo or fibrinogen administration; Clauss values upon arrival in the intensive care unit. n+116. AUC: area under the curve. British Journal of Anaesthesia 2016 116, 618-623DOI: (10.1093/bja/aev539) Copyright © 2016 The Author(s) Terms and Conditions
Fig 3 Difference between expected (22 mm) and observed FIBTEM maximum clot firmness (MCF) after fibrinogen concentrate supplementation. British Journal of Anaesthesia 2016 116, 618-623DOI: (10.1093/bja/aev539) Copyright © 2016 The Author(s) Terms and Conditions
Fig 4 Linear regression analysis for association between fibrinogen concentrate dose and increase in FIBTEM maximum clot firmness (MCF) after dosing. British Journal of Anaesthesia 2016 116, 618-623DOI: (10.1093/bja/aev539) Copyright © 2016 The Author(s) Terms and Conditions